An observational study in RSV, sponsored by University of California, San Diego. Active, not recruiting at 1 site in Botswana. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by University of California, San Diego · Observational
The goal of this mixed methods study is to engage stakeholders to develop a health economic model to estimate the costs, health benefits, and value of respiratory syncytial virus (RSV) prevention strategies. The model will help decision-makers in Botswana determine whether and how to introduce RSV prevention interventions for infants, including monoclonal antibodies.
The main questions the study aims to answer are:
How could RSV prevention strategies be delivered to infants in Botswana?
What costs, health benefits, and implementation factors should be included in a health economic model?
What information do policymakers, healthcare providers, funders, researchers, and other stakeholders need to make decisions about RSV prevention?
Participants will include key stakeholders involved in health policy, clinical care, financing, research, and child health in Botswana. Participants may be asked to complete an interview, take part in a stakeholder workshop, complete a survey, and help review or interpret model findings. The study will not test an RSV product in infants or provide medical treatment.
This mixed-methods observational study will develop a stakeholder-informed health economic model to evaluate potential respiratory syncytial virus (RSV) prevention strategies for infants in Botswana, including RSV monoclonal antibodies. The study will not administer an RSV prevention product to infants or assign participants to a medical intervention.
The study will engage policymakers, healthcare providers, funders, researchers, and patient representatives to identify the information needed to support decision-making about RSV prevention in Botswana. Study activities will include stakeholder advisory group meetings, semi-structured interviews, a structured stakeholder workshop, surveys, and model review activities.
Stakeholder input will be used to define key features of the health economic model, including target populations, delivery settings, implementation strategies, time horizon, costs, health outcomes, equity considerations, and uncertainty analyses. The model will estimate the potential cost-effectiveness and budget impact of RSV monoclonal antibody implementation among infants in Botswana, including strategies for all eligible infants and for higher-risk groups such as infants born preterm, infants exposed to HIV, and infants born during RSV season.
The study will also evaluate the stakeholder engagement process. Stakeholder advisory group members will be asked about their experiences participating in model development and their perceptions of whether the final model is relevant, usable, credible, and helpful for country-level decision-making. Findings will be used to refine the model and develop materials to support future stakeholder-engaged health economic modeling in Botswana and similar settings.
University of California, San Diego is the lead sponsor of 980 studies on the registry; 195 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
We will establish a 20-member stakeholder advisory board representing policymakers (n=5), funders (n=3), healthcare providers (n=5), researchers (n=2), and leaders representing patient groups (n=5).
Inclusion Criteria
Expertise or Role:
Up to 40 stakeholders will participate in an interview and up to 20 will participate in a workshop on health economic modeling and a pre/post survey.
Completion of a stakeholder-informed health economic model to evaluate RSV prevention strategies for infants in Botswana.
Model completion will be measured as the number of pre-specified model development milestones completed. Milestones include: finalizing the model structure; identifying and documenting model input parameters; programming the model; conducting internal model checks; generating base-case results; conducting sensitivity analyses; reviewing model assumptions and preliminary results with stakeholders; and producing final model outputs for dissemination.
Time frame: July 1, 2026 to December 30, 2027
Stakeholder-rated quality of engagement
Stakeholder engagement will be assessed using a survey adapted from established engagement domains, including respect, trust, legitimacy, fairness, competence, and accountability. Participants involved in workshops and model-development activities will be asked to rate the extent to which the engagement process was inclusive, transparent, respectful, and useful for shaping the health economic model and its outputs.
Time frame: July 1, 2026 to December 30, 2027
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Diego →